Anticorps Polyclonal de lapin anti-VEGFR-1/FLT-1
VEGFR-1/FLT-1 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, souris et plus (2)
Applications
WB, IHC, IF/ICC, IP, ELISA
Conjugaison
Non conjugué
N° de cat : 13687-1-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules HEK-293, tissu placentaire humain, tissu pulmonaire de souris |
| Résultats positifs en IP | cellules A549 |
| Résultats positifs en IHC | tissu de carcinome à cellules rénales humain, il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
| Résultats positifs en IF/ICC | cellules HeLa |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| Immunoprécipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochimie (IHC) | IHC : 1:1000-1:4000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:10-1:100 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| WB | See 48 publications below |
| IHC | See 8 publications below |
| IF | See 5 publications below |
| IP | See 2 publications below |
| FC | See 1 publications below |
Informations sur le produit
13687-1-AP cible VEGFR-1/FLT-1 dans les applications de WB, IHC, IF/ICC, IP, ELISA et montre une réactivité avec des échantillons Humain, souris
| Réactivité | Humain, souris |
| Réactivité citée | rat, bovin, Humain, souris |
| Hôte / Isotype | Lapin / IgG |
| Clonalité | Polyclonal |
| Type | Anticorps |
| Immunogène | VEGFR-1/FLT-1 Protéine recombinante Ag4558 |
| Nom complet | fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) |
| Masse moléculaire calculée | 1338 aa, 151 kDa |
| Poids moléculaire observé | 55-60 kDa |
| Numéro d’acquisition GenBank | BC039007 |
| Symbole du gène | VEGFR-1/FLT-1 |
| Identification du gène (NCBI) | 2321 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par affinité contre l'antigène |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
Vascular endothelial growth factor receptor-1 (VEGFR-1, FLT-1) is a receptor tyrosine kinase belonging to the VEGFR family. VEGF is a key regulator of physiological angiogenesis and has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders, and other conditions. The biological effects of VEGF are mediated by VEGFR-1 and VEGFR-2. Both the two receptors have seven immunoglobulin-like repeats in the extracellular domain, a single transmembrane region and a tyrosine kinase domain. VEGFR-1 binds VEGFA, PIGF, and VEGFB, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Two isoforms of VEGFR-1 exist, a full-length transmembrane form and a short soluble form (sVEGFR-1) consisting of only the extracellular ligand-binding domain. (PMID: 12778165; 17109193; 8806634)
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for VEGFR-1/FLT-1 antibody 13687-1-AP | Download protocol |
| IHC protocol for VEGFR-1/FLT-1 antibody 13687-1-AP | Download protocol |
| IF protocol for VEGFR-1/FLT-1 antibody 13687-1-AP | Download protocol |
| IP protocol for VEGFR-1/FLT-1 antibody 13687-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
ACS Appl Mater Interfaces Biocompatible Chitin Hydrogel Incorporated with PEDOT Nanoparticles for Peripheral Nerve Repair. | ||
Hypertension Statins Prevent the Deleterious Consequences of Placental Chemerin Upregulation in Preeclampsia | ||
Biomed Pharmacother Lychee seed polyphenol ameliorates DR via inhibiting inflammasome/apoptosis and angiogenesis in hRECs and db/db mice | ||
Stem Cells Heparanase released from mesenchymal stem cells activates integrin beta1/HIF-2alpha/Flk-1 signaling and promotes endothelial cell migration and angiogenesis. | ||
J Ethnopharmacol Diterpenoid tanshinones inhibit gastric cancer angiogenesis through the PI3K/Akt/mTOR signaling pathway | ||
Clin Sci (Lond) Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability. |






